Microcirculatory effects of a course of the flyuktuorez mexidol in patients with chronic generalized periodontitis of moderate severity


Cite item

Full Text

Abstract

The results of monitoring for 160 patients aged 35 to 75 years with a verified diagnosis of chronic generalized periodontitis of moderate severity. It is established that flyuktuorez helps to improve values for clinical and rheographic indices and indicators of laser Doppler flowmetry by improving microcirculation. It is shown that the rate of flyuktuorez mildronata beneficial effects on myogenic regulation, and flyuktuorez nivalin - neurogenic regulation of vascular tone. Flyuktuorez Actovegin is quite effective in cases where it is not revealed the predominance of violations of either myogenic or neurogenic regulation.

About the authors

M. A Amkhadova

«M.F. Vladimirsky Moscow regional research clinical Institute»; «Moscow region dental clinic»

129110, Moscow

Anna Vladimirovna P’yanzina

«M.F. Vladimirsky Moscow regional research clinical Institute»; «Moscow region dental clinic»

Email: megakafedra@gmail.com
129110, Moscow

M. Yu Gerasimenko

«M.F. Vladimirsky Moscow regional research clinical Institute»; «Moscow region dental clinic»

129110, Moscow

M. M Gamzatov

«M.F. Vladimirsky Moscow regional research clinical Institute»; «Moscow region dental clinic»

129110, Moscow

M. I Soykher

«M.F. Vladimirsky Moscow regional research clinical Institute»; «Moscow region dental clinic»

129110, Moscow

Z. R Muzaeva

«M.F. Vladimirsky Moscow regional research clinical Institute»; «Moscow region dental clinic»

129110, Moscow

References

  1. Дмитриева Л.А. Пародонтит. М.: Медпресс-информ, 2007.
  2. Кречина Е.К. Мониторинг реактивности микрососудов пародонта с помощью лазерной допплеровской флоуметрии. Применение лазерной допплеровской флуометрии в медицинской практике: Материалы третьего Всероссийского симпозиума. М.; 2000: 133-4.
  3. Ушакова Г.Б. Применение флюктуирующих токов в комплексной терапии пародонтита: Дисс. … канд. мед. наук. М.; 1990.
  4. Buchmayer F., Pleiner J., Elmlinger M.W., Lauer G., Nell G., Sitte H.H. Actovegin®: a biological drug for more than 5 decades. Wien Med. Wochenschr. 2011; 161(3-4): 80-8.
  5. Jaudzems K., Kuka J., Gutsaits A., Zinovjevs K., Kalvinsh I., Liepinsh E., Liepinsh E., Dambrova M. Inhibition of carnitine acetyltransferase by mildronate, a regulator of energy metabolism. J. Enzyme Inhib Med Chem. 2009; 24(6): 1269-75.
  6. Osborn G.G., Saunders A.V. Current treatments for patients with Alzheimer disease. J. Am. Osteopath Assoc. 2010; 110(9 Suppl 8): 16-26.
  7. Petersen P.E., Ogaw H. Strengthening the prevention of periodontal disease: the WHO approach. J. Periodontol. 2005. 76(12): 2187-93.
  8. Pupure J., Isajevs S., Skapare E., Rumaks J., Svirskis S., Svirina D., Kalvinsh I., Klusa V. Neuroprotective properties of mildronate, a mitochondria-targeted small molecule. Neurosci Lett. 2010; 470(2): 100-5.

Copyright (c) 2015 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies